Highest-materiality recent filing
Vivani Medical reports Q1 2026 net loss of $6.8M; SLIM-1 trial on track for mid-2026
Net loss of $6.8M in Q1 2026, up from $6.3M in Q1 2025; R&D expense $4.4M (+4% YoY).
Vivani Medical reports FY2025 net loss $26.6M; advances semaglutide implant NPM-139 towards Phase 1
FY2025 net loss $26.6M vs $23.5M in FY2024; R&D expenses $18.1M up 15% YoY.
Vivani Medical prices $4.5M common stock offering; Chairman participates in private placement
Gross proceeds of $4.5M from registered direct offering (1.69M shares) and private placement (1.35M shares) at $1.48/share.
Vivani Medical Q3 net loss $6.5M; plans Phase 1 semaglutide implant study in H1 2026
Net loss of $6.5M in Q3 2025 vs $6.0M in Q3 2024; cash down to $4.0M from $19.7M at year-end 2024.
Vivani Medical prices $15.7M equity offering; Chairman participates in $6.0M private placement
Registered direct offering of 6M shares and private placement of 3.7M shares priced at $1.62/share for total gross proceeds of ~$15.7M.
Vivani Medical withdraws Cortigent spin-off record date due to US government shutdown
Withdrew record date of October 8, 2025 for proposed spin-off of Cortigent subsidiary.
Vivani sets Oct 8 record date for Cortigent spin-off; Cortigent to trade as CRGT
Record date for Cortigent spin-off is October 8, 2025; distribution date and ratio to be announced later.
Vivani Medical files corporate slides; no specific material changes apparent from filing text
Corporate slide presentation filed as Exhibit 99.1, date-stamped September 9, 2025.
Vivani Medical plans Phase 1/2 trials for NPM-139 semaglutide implant; H1 2026 start
NPM-139 is a semaglutide implant for chronic weight management in obese/overweight patients.
Vivani Medical raises $10M, reports Q2 loss of $7.1M, advances semaglutide implant NPM-139
Raised $10M via private placement of 7.94M shares at $1.26/share with director-affiliated entity.
Preliminary Q2 2025 cash and cash equivalents $6.8M, plus $11.25M committed capital through March 2026.
Vivani Medical stockholders elect board, ratify auditor, approve say-on-pay at annual meeting
Elected all six director nominees: Gregg Williams, Aaron Mendelsohn, Dean Baker, Alexandra Popoff, Adam Mendelsohn, Daniel Bradbury.
Vivani Medical reports exenatide implant cuts liver fat 82% in obese mice
Exenatide implant reduced liver fat by 82% vs sham in high-fat diet obese mice after 12 weeks (Oil Red O staining).
Vivani Medical appoints Anthony Baldor as CFO, Brigid Makes resigns
CFO Brigid Makes resigns effective June 15, 2025; no disagreement with company.
Vivani Medical files Form 10 for spin-off of Cortigent; expects Nasdaq listing in Q3 2025
Cortigent files Form 10 to spin off from Vivani as independent Nasdaq company; completion expected Q3 2025.
On June 11, 2025, the board of directors (the “Board”) of the Company appointed Anthony Baldor, to serve as the Company’s Chief Financial Officer, Principal Financial Officer and Principal Accounting Officer, effective June 15, 2025.
On June 10, 2025, Brigid Makes notified Vivani Medical, Inc. (the “Company”) of her decision to resign from her role as Chief Financial Officer, Principal Financial Officer and Principal Accounting Officer, of the Company, effective as of June 15, 2025.
Max materiality 0.80 · Median 0.60 · Most common event other_material